Comparative Pharmacology
Head-to-head clinical analysis: LUNELLE versus NEXPLANON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUNELLE versus NEXPLANON.
LUNELLE vs NEXPLANON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lunelle is a combination contraceptive injection containing medroxyprogesterone acetate and estradiol cypionate. It suppresses gonadotropin secretion, inhibiting ovulation and thickening cervical mucus to prevent sperm penetration.
Progestin-only contraceptive that suppresses ovulation primarily by inhibiting the mid-cycle LH surge. It also thickens cervical mucus, impeding sperm penetration, and alters endometrial lining.
150 mg intramuscular injection on day 5 of menstrual cycle, then every 90 days thereafter.
68 mg subdermal implant inserted in the inner upper arm; provides contraception for up to 3 years.
None Documented
None Documented
Terminal elimination half-life of 20-30 hours in healthy adults; prolonged to 40-60 hours in moderate renal impairment (CrCl 30-50 mL/min). Clinically, steady state reached in 4-5 days.
Terminal elimination half-life approximately 25 hours (range 20-30 hours) after removal; steady-state achieved within 3-4 days; clinical effect persists for 3-4 weeks post-removal due to residual subcutaneous depot.
Primarily renal (~70% as unchanged drug and inactive metabolites), with ~20% biliary/fecal elimination. Minimal dose recovered in feces as parent compound.
Renal (40-50% as metabolites), fecal (30-40% as metabolites), with <1% unchanged in urine; enterohepatic circulation contributes to prolonged elimination.
Category C
Category C
Contraceptive
Contraceptive